Efficacy of mizoribine treatment in patients with SjÖgren’s syndrome: an open pilot trial
Efficacy of mizoribine treatment in patients with SjÖgren’s syndrome: an open pilot trial
复制标题
咪唑利滨治疗干燥综合征患者的疗效：一项开放的试点试验
作者：
S. Nakayamada;K. Saito;K. Nakatsuka;K. Nakano;M. Tokunaga;N. Sawamukai;S. Tsujimura;M. Nawata;Yoshiya Tanaka
本研究的目的是评价咪唑立宾治疗干燥综合征的疗效和安全性。对确诊为干燥综合征的4 0例干燥综合征患者给予咪唑立宾15 0 mg/d口服，疗程12个月。治疗3、6和12个月后，唾液分泌物的百分比变化分别为+112.2%(P≪0.001)、+119.9%(P≪0.001)和+147.3%(P≪0.001)。治疗12个月后血清免疫球蛋白水平为(1969.4±620.0) mg/dl，治疗前为(2094.3±746.6) mg/dl，两组比较差异有统计学意义(P<≪)。患者临床体征和症状的视觉模拟评分由治疗开始时的7 2±2 3 cm显著改善至治疗12个月后的5 0±1 9 cm(P≪0.001)。医生使用10 cm视觉模拟评分的评估也有类似的改善：治疗开始时为7.1±1.6 cm，治疗12个月后为5.2±1.9 cm(P≪0.001)。在安全性方面，未观察到严重不良反应。虽然需要一项对照研究来阐明咪唑立宾的疗效，但这些初步观察表明，它通过改善干燥综合征患者的免疫异常而有效地改善了腺体症状。
The aim of this study was to evaluate the efficacy and safety of mizoribine in patients with SjÖgren’s syndrome. Forty patients with sicca syndrome, whose conditions were definitely diagnosed as SjÖgren’s syndrome, were given mizoribine orally at a dosage of 150 mg/day for 12 months. The percentage change in salivary secretion after 3, 6, and 12 months of the therapy increased to +112.2% (P ≪ 0.001), +119.9% (P ≪ 0.01), and +147.3% (P ≪ 0.001), respectively, compared with the baseline. Serum IgG levels decreased significantly throughout the study, and the level was 1969.4 ± 620.0 mg/dl after treatment for 12 months compared with the pretreatment value of 2094.3 ± 746.6 mg/dl (P ≪ 0.05). The patient’s assessment of clinical signs and symptoms on a 10-cm visual analog scale improved significantly from 7.2 ± 2.3 cm at the start of the treatment to 5.0 ± 1.9 cm after 12 months (P ≪ 0.001). There was a similar improvement in the physician’s assessment using the 10-cm visual analog scale: 7.1 ± 1.6 cm at the start of the treatment and 5.2 ± 1.9 cm after 12 months (P ≪ 0.001). With regard to safety, no serious adverse reactions were observed. Although a controlled study would be required to clarify the efficacy of mizoribine, these preliminary observations indicate its efficacy for ameliorating glandular symptoms through improvements in immune abnormalities in patients with SjÖgren’s syndrome.
DOI：
10.1073/pnas.95.13.7538
发表时间：
1998-06-23
影响因子：
11.1
作者：
Robinson, CP;Brayer, J;Humphreys-Beher, MG
通讯作者：
Humphreys-Beher, MG